Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one yea ...
Wall Street Journal20d
Russia Trots Out Its Newest Weapons in Ukraine: Horses
DRUZHKIVKA, Ukraine—On the eastern front here, Russia is saddling up a mainstay of battlefields from earlier centuries to counter Ukraine’s drone army: horses and donkeys. The hoofed mammals ...